In last trading session, Summit Therapeutics Inc. (NASDAQ:SMMT) saw 1.42 million shares changing hands with its beta currently measuring 0.93. Company’s recent per share price level of $1.24 trading at -$0.11 or -8.15% at ring of the bell on the day assigns it a market valuation of $268.86M. That closing price of SMMT’s stock is at a discount of -427.42% from its 52-week high price of $6.54 and is indicating a premium of 29.03% from its 52-week low price of $0.88. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.72 million shares which gives us an average trading volume of 2.04 million if we extend that period to 3-months.
Summit Therapeutics Inc. (NASDAQ:SMMT) trade information
Upright in the red during last session for losing -8.15%, in the last five days SMMT remained trading in the red while hitting it’s week-highest on Thursday, 09/15/22 when the stock touched $1.24 price level, adding 13.89% to its value on the day. Summit Therapeutics Inc.’s shares saw a change of -53.90% in year-to-date performance and have moved -6.06% in past 5-day. Summit Therapeutics Inc. (NASDAQ:SMMT) showed a performance of -23.93% in past 30-days. Number of shares sold short was 0.88 million shares which calculate 3.09 days to cover the short interests.
Summit Therapeutics Inc. (SMMT) estimates and forecasts
This year revenue growth is estimated to fall -92.30% from the last financial year’s standing.
Company posted $4.55 million and $192k of sales in current and next quarters respectively a year earlier.
Summit Therapeutics Inc. is more likely to be releasing its next quarterly report between March 15 and March 21 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Summit Therapeutics Inc. (NASDAQ:SMMT)’s Major holders
Insiders are in possession of 73.86% of company’s total shares while institution are holding 11.37 percent of that, with stock having share float percentage of 43.49%. Investors also watch the number of corporate investors in a company very closely, which is 11.37% institutions for Summit Therapeutics Inc. that are currently holding shares of the company. Polar Capital Holdings Plc is the top institutional holder at SMMT for having 6.27 million shares of worth $15.37 million. And as of Mar 30, 2022, it was holding 6.39% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 1.37 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 1.39% of outstanding shares, having a total worth of $3.34 million.
On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Small Cap Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 30, 2022, the former fund manager was holding 0.73 million shares of worth $1.79 million or 0.75% of the total outstanding shares. The later fund manager was in possession of 0.19 million shares on Apr 29, 2022, making its stake of worth around $0.31 million in the company or a holder of 0.20% of company’s stock.